Testicular germ cell tumours: Predisposition genes and the male germ cell niche

Nature Reviews Cancer

Volumn 11, Issue 4, 2011, Pages 278-288

  Gilbert, Duncan ^a,b   Rapley, Elizabeth ^b   Shipley, Janet ^b  

^a ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CHEMOKINE RECEPTOR CXCR4; CHORIONIC GONADOTROPIN; CISPLATIN; CYCLIN D2; ETOPOSIDE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; IMATINIB; K RAS PROTEIN; LACTATE DEHYDROGENASE; PHOSPHATIDYLINOSITOL 3 KINASE; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; SUNITINIB; TELOMERASE; TUMOR MARKER; VASCULOTROPIN;

ANEUPLOIDY; AUTOCRINE EFFECT; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER RISK; CARCINOGENESIS; CAUCASIAN; CELL GROWTH; CELL LINEAGE; CELL MIGRATION; CELL SURVIVAL; CHROMOSOME 12P; CRYPTORCHISM; EMBRYONIC STEM CELL; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENE TARGETING; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENOME IMPRINTING; GERM CELL; GERM CELL TUMOR; HUMAN; MALE GENITAL TRACT MALFORMATION; MULTIPLE CYCLE TREATMENT; NON SEMINOMATOUS GERMINOMA; ONSET AGE; PLURIPOTENT STEM CELL; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEMINOMA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SPERMATOGENESIS; TESTICULAR GERM CELL TUMOR; TESTIS TUMOR;

ADOLESCENT; ADULT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; STEM CELL NICHE; TESTICULAR NEOPLASMS;

EID: 79953034087     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3021     Document Type: Review

References (197)

1. Oosterhuis, J. W. & Looijenga, L. H. Testicular germ-cell tumours in a broader perspective. Nature Rev. Cancer 5, 210-222 (2005). (Pubitemid 40314952)
2. Horwich, A., Shipley, J. & Huddart, R. Testicular germ-cell cancer. Lancet 367, 754-765 (2006). (Pubitemid 43326294)
3. Atkin, N. B. & Baker, M. C. Specific chromosome change, i(12p), in testicular tumours? Lancet 2, 1349 (1982).
4. Atkin, N. B. & Baker, M. C. i(12p): specific chromosomal marker in seminoma and malignant teratoma of the testis? Cancer Genet. Cytogenet. 10, 199-204 (1983). (Pubitemid 13013934)
5. Sandberg, A. A., Meloni, A. M. & Suijkerbuijk, R. F. Reviews of chromosome studies in urological tumors. III. Cytogenetics and genes in testicular tumors. J.-Urol. 155, 1531-1556 (1996). (Pubitemid 26126947)
6. Henegariu, O., Vance, G. H., Heiber, D., Pera, M. & Heerema, N. A. Triple-color FISH analysis of 12p amplification in testicular germ-cell tumors using 12p band-specific painting probes. J.-Mol. Med. 76, 648-655 (1998). (Pubitemid 28361883)
7. Rodriguez, S. et-al. Expression profile of genes from 12p in testicular germ cell tumors of adolescents and adults associated with i(12p) and amplification at 12p11.2-p12. Oncogene 22, 1880-1891 (2003). (Pubitemid 36513147)
8. Roelofs, H. et-al. Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testis. Am. J.-Pathol. 157, 1155-1166 (2000).
9. Summersgill, B. et-al. Molecular cytogenetic analysis of adult testicular germ cell tumours and identification of regions of consensus copy number change. Br. J. Cancer 77, 305-313 (1998). (Pubitemid 28029548)
10. Zafarana, G. et-al. 12p-amplicon structure analysis in testicular germ cell tumors of adolescents and adults by array CGH. Oncogene 22, 7695-7701 (2003). (Pubitemid 37464104)
11. Clark, A. T. et-al. Human STELLAR, NANOG, and GDF3 genes are expressed in pluripotent cells and map to chromosome 12p13, a hotspot for teratocarcinoma. Stem Cells 22, 169-179 (2004). (Pubitemid 38282632)
12. Korkola, J. E. et-al. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in-vivo differentiation of human male germ cell tumors. Cancer Res. 66, 820-827 (2006).
13. Giuliano, C. J. et-al. Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity. Biochim. Biophys. Acta 1731, 48-56 (2005).
14. Skakkebaek, N. E. Possible carcinoma-in-situ of the testis. Lancet 2, 516-517 (1972).
15. Jacobsen, G. K. & Henriques, U. V. A fetal testis with intratubular germ cell neoplasia (ITGCN). Mod. Pathol. 5, 547-549 (1992).
16. Satge, D., Jacobsen, G. K., Cessot, F., Raffi, F. & Vekemans, M. A fetus with Down syndrome and intratubular germ cell neoplasia. Pediatr. Pathol. Lab. Med. 16, 107-112 (1996). (Pubitemid 26051406)
17. Jacobsen, G. K., Henriksen, O. B. & von der Maase, H. Carcinoma in-situ of testicular tissue adjacent to malignant germ-cell tumors: a study of 105 cases. Cancer 47, 2660-2662 (1981). (Pubitemid 11113732)
18. Linke, J., Loy, V. & Dieckmann, K. P. Prevalence of testicular intraepithelial neoplasia in healthy males. J.-Urol. 173, 1577-1579 (2005). (Pubitemid 40524774)
19. Oosterhuis, J. W., Stoop, H., Honecker, F. & Looijenga, L. H. Why human extragonadal germ cell tumours occur in the midline of the body: old concepts, new perspectives. Int. J.-Androl. 30, 256-264 (2007).
20. Fossa, S. D. Long-term sequelae after cancer therapy-survivorship after treatment for testicular cancer. Acta Oncol. 43, 134-141 (2004). (Pubitemid 38478899)
21. Huddart, R. A. et-al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J. Clin. Oncol. 21, 1513-1523 (2003).
22. Meinardi, M. T. et-al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J. Clin. Oncol. 18, 1725-1732 (2000).
23. van den Belt-Dusebout, A. W. et-al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J. Clin. Oncol. 24, 467-475 (2006).
24. Travis, L. B. et-al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J.-Natl Cancer Inst. 97, 1354-1365 (2005).
25. van den Belt-Dusebout, A. W. et-al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J. Clin. Oncol. 25, 4370-4378 (2007).
26. Moul, J. W. et-al. Testicular cancer in blacks. A multicenter experience. Cancer 73, 388-393 (1994).
27. Forman, D. et-al. Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis. Br. J. Cancer 65, 255-262 (1992).
28. Heimdal, K. et-al. Familial testicular cancer in Norway and southern Sweden. Br. J. Cancer 73, 964-969 (1996). (Pubitemid 26110173)
29. Hemminki, K., Li, X. & Czene, K. Familial risk of cancer: data for clinical counseling and cancer genetics. Int. J. Cancer 108, 109-114 (2004). (Pubitemid 37444452)
30. Czene, K., Lichtenstein, P. & Hemminki, K. Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish Family Cancer Database. Int. J. Cancer 99, 260-266 (2002). (Pubitemid 34309484)
31. Fletcher, O. & Houlston, R. S. Architecture of inherited susceptibility to common cancer. Nature Rev. Cancer 10, 353-361 (2010).
32. Crockford, G. P. et-al. Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum. Mol. Genet. 15, 443-451 (2006).
33. Rajpert-de Meyts, E. & Hoei-Hansen, C. E. From gonocytes to testicular cancer: the role of impaired gonadal development. Ann. N. Y.-Acad. Sci. 1120, 168-180 (2007).
34. Ekbom, A., Richiardi, L., Akre, O., Montgomery, S. M. & Sparen, P. Age at immigration and duration of stay in relation to risk for testicular cancer among Finnish immigrants in Sweden. J.-Natl Cancer Inst. 95, 1238-1240 (2003). (Pubitemid 37069554)
35. Montgomery, S. M., Granath, F., Ehlin, A., Sparen, P. & Ekbom, A. Germ-cell testicular cancer in offspring of Finnish immigrants to Sweden. Cancer Epidemiol. Biomarkers Prev. 14, 280-282 (2005). (Pubitemid 40165316)
36. Strohsnitter, W. C. et-al. Cancer risk in men exposed in-utero to diethylstilbestrol. J.-Natl Cancer Inst. 93, 545-551 (2001).
37. Forman, D. et al. Aetiology of testicular cancer: association with congenital abnormalities, age at puberty, infertility, and exercise. United Kingdom Testicular Cancer Study Group. BMJ 308, 1393-1399 (1994). (Pubitemid 24159114)
38. Dieckmann, K. P. & Pichlmeier, U. Clinical epidemiology of testicular germ cell tumors. World J.-Urol. 22, 2-14 (2004). (Pubitemid 41406567)
39. Baker, J. A., Buck, G. M., Vena, J. E. & Moysich, K. B. Fertility patterns prior to testicular cancer diagnosis. Cancer Causes Control 16, 295-299 (2005). (Pubitemid 40897848)
40. Doria-Rose, V. P., Biggs, M. L. & Weiss, N. S. Subfertility and the risk of testicular germ cell tumors (United States). Cancer Causes Control 16, 651-656 (2005). (Pubitemid 41110955)
41. Hotaling, J. M. & Walsh, T. J. Male infertility: a risk factor for testicular cancer. Nature Rev. Urol. 6, 550-556 (2009).
42. Walsh, T. J., Croughan, M. S., Schembri, M., Chan,-J. M. & Turek, P. J. Increased risk of testicular germ cell cancer among infertile men. Arch. Intern. Med. 169, 351-356 (2009).
43. Skakkebaek, N. E., Rajpert-De Meyts, E. & Main, K. M. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum. Reprod. 16, 972-978 (2001). (Pubitemid 32451837)
44. Akre, O. & Richiardi, L. Does a testicular dysgenesis syndrome exist? Hum. Reprod. 24, 2053-2060 (2009).
45. Schnack, T. H., Poulsen, G., Myrup, C., Wohlfahrt, J. & Melbye, M. Familial coaggregation of cryptorchidism, hypospadias, and testicular germ cell cancer: a nationwide cohort study. J. Natl Cancer Inst. 102, 187-192 (2010).
46. Ohinata, Y. et-al. A signaling principle for the specification of the germ cell lineage in mice. Cell 137, 571-584 (2009).
47. Saitou, M., Barton, S. C. & Surani, M. A. A molecular programme for the specification of germ cell fate in mice. Nature 418, 293-300 (2002). (Pubitemid 34790674)
48. Nakamura, T. et-al. PGC7/Stella protects against DNA demethylation in early embryogenesis. Nature Cell Biol. 9, 64-71 (2007). (Pubitemid 46024198)
49. Farini, D., La Sala, G., Tedesco, M. & De Felici, M. Chemoattractant action and molecular signaling pathways of Kit ligand on mouse primordial germ cells. Dev. Biol. 306, 572-583 (2007). (Pubitemid 46873531)
50. Besmer, P. et-al. The kit-ligand (steel factor) and its receptor c-kit/W: pleiotropic roles in gametogenesis and melanogenesis. Dev. Suppl. 125-137 (1993). (Pubitemid 24139754)
51. De Felici, M. et-al. Experimental approaches to the study of primordial germ cell lineage and proliferation. Hum. Reprod. Update 10, 197-206 (2004). (Pubitemid 38744866)
52. De Miguel, M. P., Cheng, L., Holland, E. C., Federspiel, M. J. & Donovan, P. J. Dissection of the c-Kit signaling pathway in mouse primordial germ cells by retroviral-mediated gene transfer. Proc. Natl Acad. Sci. USA 99, 10458-10463 (2002).
53. Runyan, C. et-al. Steel factor controls midline cell death of primordial germ cells and is essential for their normal proliferation and migration. Development 133, 4861-4869 (2006). (Pubitemid 46085052)
54. Doitsidou, M. et-al. Guidance of primordial germ cell migration by the chemokine SDF-1. Cell 111, 647-659 (2002). (Pubitemid 35441247)
55. Knaut, H. & Schier, A. F. Clearing the path for germ cells. Cell 132, 337-339 (2008). (Pubitemid 351200514)
56. Molyneaux, K. A. et-al. The chemokine SDF1/CXCL12 and its receptor CXCR4 regulate mouse germ cell migration and survival. Development 130, 4279-4286 (2003). (Pubitemid 37185317)
57. Boldajipour, B. et-al. Control of chemokine-guided cell migration by ligand sequestration. Cell 132, 463-473 (2008). (Pubitemid 351191997)
58. Boldajipour, B. & Raz, E. What is left behind-quality control in germ cell migration. Sci. STKE 2007, pe16 (2007).
59. Allegrucci, C., Thurston, A., Lucas, E. & Young, L. Epigenetics and the germline. Reproduction 129, 137-149 (2005). (Pubitemid 40340102)
60. Molyneaux, K. & Wylie, C. Primordial germ cell migration. Int. J.-Dev. Biol. 48, 537-544 (2004). (Pubitemid 39360404)
61. Maldonado-Saldivia, J. et-al. Dppa2 and Dppa4 are closely linked SAP motif genes restricted to pluripotent cells and the germ line. Stem Cells 25, 19-28 (2007). (Pubitemid 46052971)
62. Western, P. Foetal germ cells: striking the balance between pluripotency and differentiation. Int. J.-Dev. Biol. 53, 393-409 (2009).
63. Yamaguchi, S., Kimura, H., Tada, M., Nakatsuji, N. & Tada, T. Nanog expression in mouse germ cell development. Gene Expr. Patterns 5, 639-646 (2005). (Pubitemid 40796609)
64. Wawersik, M. et-al. Somatic control of germline sexual development is mediated by the JAK/STAT pathway. Nature 436, 563-567 (2005). (Pubitemid 41112930)
65. Sariola, H. & Saarma, M. Novel functions and signalling pathways for GDNF. J. Cell Sci. 116, 3855-3862 (2003). (Pubitemid 37279301)
66. Ohta, H., Tohda, A. & Nishimune, Y. Proliferation and differentiation of spermatogonial stem cells in the w/wv mutant mouse testis. Biol. Reprod. 69, 1815-1821 (2003). (Pubitemid 37505324)
67. Dadoune, J. P. New insights into male gametogenesis: what about the spermatogonial stem cell niche? Folia Histochem. Cytobiol. 45, 141-147 (2007).
68. Chen, C. et-al. ERM is required for transcriptional control of the spermatogonial stem cell niche. Nature 436, 1030-1034 (2005). (Pubitemid 41191687)
69. Buaas, F. W. et-al. Plzf is required in adult male germ cells for stem cell self-renewal. Nature Genet. 36, 647-652 (2004).
70. Costoya, J. A. et-al. Essential role of Plzf in maintenance of spermatogonial stem cells. Nature Genet. 36, 653-659 (2004).
71. Labbaye, C. et-al. A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nature Cell Biol. 10, 788-801 (2008). (Pubitemid 351927708)
72. Payne, C. J. et-al. Sin3a is required by sertoli cells to establish a niche for undifferentiated spermatogonia, germ cell tumors, and spermatid elongation. Stem Cells 28, 1424-1434 (2010).
73. Korkola, J. E. et-al. Gene expression-based classification of nonseminomatous male germ cell tumors. Oncogene 24, 5101-5107 (2005). (Pubitemid 41129087)
74. Port, M. et-al. Gene expression profiling in seminoma and nonseminoma. J. Clin. Oncol. 23, 58-69 (2005). (Pubitemid 41702623)
75. Skotheim, R. I. et-al. New insights into testicular germ cell tumorigenesis from gene expression profiling. Cancer Res. 62, 2359-2364 (2002).
76. Sperger, J. M. et-al. Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. Proc. Natl Acad. Sci. USA 100, 13350-13355 (2003).
77. Almstrup, K. et-al. Genome-wide gene expression profiling of testicular carcinoma in-situ progression into overt tumours. Br. J. Cancer 92, 1934-1941 (2005). (Pubitemid 40826144)
78. Summersgill, B., Osin, P., Lu, Y. J., Huddart, R. & Shipley, J. Chromosomal imbalances associated with carcinoma in-situ and associated testicular germ cell tumours of adolescents and adults. Br. J. Cancer 85, 213-220 (2001).
79. Draper, J. S. et-al. Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. Nature Biotech. 22, 53-54 (2004).
80. de Jong, J. et-al. Diagnostic value of OCT3/4 for pre-invasive and invasive testicular germ cell tumours. J. Pathol. 206, 242-249 (2005).
81. Subramaniam, K. & Seydoux, G. Dedifferentiation of primary spermatocytes into germ cell tumors in, C. elegans lacking the pumilio-like protein PUF-8. Curr. Biol. 13, 134-139 (2003). (Pubitemid 36154341)
82. Guan, K. et-al. Pluripotency of spermatogonial stem cells from adult mouse testis. Nature 440, 1199-1203 (2006).
83. Nathanson, K. L. et-al. The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am. J.-Hum. Genet. 77, 1034-1043 (2005).
84. Kanetsky, P. A. et-al. Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nature Genet. 41, 811-815 (2009).
85. Rapley, E. A. et-al. A genome-wide association study of testicular germ cell tumor. Nature Genet. 41, 807-810 (2009).
86. Turnbull, C. et-al. Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. Nature Genet. 42, 604-607 (2009).
87. Izquierdo, M. A. et-al. Differential expression of the c-kit proto-oncogene in germ cell tumours. J. Pathol. 177, 253-258 (1995).
88. Kemmer, K. et-al. KIT mutations are common in testicular seminomas. Am. J. Pathol. 164, 305-313 (2004). (Pubitemid 38364614)
89. Looijenga, L. H. et-al. Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ Cell tumors. Cancer Res. 63, 7674-7678 (2003).
90. McIntyre, A. et-al. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res. 65, 8085-8089 (2005). (Pubitemid 41330569)
91. Rapley, E. A. et-al. Somatic mutations of KIT in familial testicular germ cell tumours. Br. J. Cancer 90, 2397-2401 (2004).
92. Willmore-Payne, C., Layfield, L. J. & Holden, J. A. c-KIT mutation analysis for diagnosis of gastrointestinal stromal tumors in fine needle aspiration specimens. Cancer 105, 165-170 (2005). (Pubitemid 40868896)
93. Goddard, N. C. et-al. KIT and RAS signalling pathways in testicular germ cell tumours: new data and a review of the literature. Int. J. Androl. 30, 337-349 (2007).
94. Roskoski, R. Jr. Signaling by Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem. Biophys. Res. Commun. 337, 1-13 (2005). (Pubitemid 41393751)
95. Heaney, J. D., Lam, M. Y., Michelson, M. V. & Nadeau, J. H. Loss of the transmembrane but not the soluble kit ligand isoform increases testicular germ cell tumor susceptibility in mice. Cancer Res. 68, 5193-5197 (2008).
96. Sasaki, A. et-al. Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1. Cell Cycle 2, 281-282 (2003).
97. Frolov, A. et-al. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol. Cancer Ther. 2, 699-709 (2003).
98. Tsumura, Y., Toshima, J., Leeksma, O. C., Ohashi, K. & Mizuno, K. Sprouty-4 negatively regulates cell spreading by inhibiting the kinase activity of testicular protein kinase. Biochem. J. 387, 627-637 (2005). (Pubitemid 40685696)
99. Yan, W., Samson, M., Jegou, B. & Toppari, J. Bcl-w forms complexes with Bax and Bak, and elevated ratios of Bax/Bcl-w and Bak/Bcl-w correspond to spermatogonial and spermatocyte apoptosis in the testis. Mol. Endocrinol. 14, 682-699 (2000). (Pubitemid 32260512)
100. McIntyre, A. et-al. Activating mutations and/or expression levels of tyrosine kinase receptors GRB7, RAS, and BRAF in testicular germ cell tumors. Neoplasia 7, 1047-1052 (2005). (Pubitemid 44430982)
101. Olie, R. A. et-al. N- and KRAS mutations in primary testicular germ cell tumors: incidence and possible biological implications. Genes Chromosom. Cancer 12, 110-116 (1995).
102. McIntyre, A. et-al. Defining minimum genomic regions of imbalance involved in testicular germ cell tumors of adolescents and adults through genome wide microarray analysis of cDNA clones. Oncogene 23, 9142-9147 (2004). (Pubitemid 40013082)
103. Gilbert, D. C. et-al. Clinical and biological significance of CXCL12 and CXCR4 expression in adult testes and germ cell tumours of adults and adolescents. J. Pathol. 217, 94-102 (2009).
104. Mosselman, S. et-al. Aberrant platelet-derived growth factor α-receptor transcript as a diagnostic marker for early human germ cell tumors of the adult testis. Proc. Natl Acad. Sci. USA 93, 2884-2888 (1996). (Pubitemid 26116243)
105. Mandoky, L., Geczi, L., Bodrogi, I., Toth, J. & Bak, M. Expression of HER-2/neu in testicular tumors. Anticancer Res. 23, 3447-3451 (2003). (Pubitemid 36975447)
106. Gilbert, D. C. et-al. Minimum regions of genomic imbalance in stage I testicular embryonal carcinoma and association of 22q loss with relapse. Genes Chromosom. Cancer 50, 186-195 (2011).
107. Campbell, P. M. & Der, C. J. Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin. Cancer Biol. 14, 105-114 (2004). (Pubitemid 38234752)
108. Cox, A. D. & Der, C. J. The dark side of Ras: regulation of apoptosis. Oncogene 22, 8999-9006 (2003). (Pubitemid 38121700)
109. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nature Rev. Cancer 3, 11-22 (2003). (Pubitemid 37328883)
110. Marte, B. M. & Downward, J. PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem. Sci. 22, 355-358 (1997).
111. Moe-Behrens, G. H. et-al. Akt/PTEN signaling mediates estrogen-dependent proliferation of primordial germ cells in-vitro. Mol. Endocrinol. 17, 2630-2638 (2003).
112. Di Vizio, D. et-al. Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors. Oncogene 24, 1882-1894 (2005). (Pubitemid 40462790)
113. Teng, D. H. et-al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 57, 5221-5225 (1997).
114. Kimura, T. et-al. Conditional loss of PTEN leads to testicular teratoma and enhances embryonic germ cell production. Development 130, 1691-1700 (2003). (Pubitemid 36527527)
115. Sommerer, F. et-al. Mutations of BRAF and RAS are rare events in germ cell tumours. Int. J. Cancer 113, 329-335 (2005). (Pubitemid 39628326)
116. Honecker, F. et-al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J. Clin. Oncol. 27, 2129-2136 (2009).
117. Kortesidis, A. et-al. Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells. Blood 105, 3793-3801 (2005). (Pubitemid 40656121)
118. Dorsam, R. T. & Gutkind, J. S. G-protein-coupled receptors and cancer. Nature Rev. Cancer 7, 79-94 (2007). (Pubitemid 46164746)
119. Cabioglu, N. et-al. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin. Cancer Res. 11, 5686-5693 (2005). (Pubitemid 41170291)
120. Kodama, J., Hasengaowa, Seki, N., Kusumoto, T. & Hiramatsu, Y. Expression of the CXCR4 and CCR7 chemokine receptors in human endometrial cancer. Eur. J. Gynaecol. Oncol. 28, 370-375 (2007). (Pubitemid 47535548)
121. Muller, A. et-al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001). (Pubitemid 32225831)
122. Su, L. et-al. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clin. Cancer Res. 11, 8273-8280 (2005). (Pubitemid 41746937)
123. Barbero, S. et-al. Stromal cell-derived factor 1α stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res. 63, 1969-1974 (2003). (Pubitemid 36460865)
124. Kijima, T. et-al. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res. 62, 6304-6311 (2002). (Pubitemid 35244485)
125. Yoon, Y. et-al. CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res. 67, 7518-7524 (2007). (Pubitemid 47206582)
126. Chinni, S. R. et-al. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment- associated CXCL12. Prostate 66, 32-48 (2006). (Pubitemid 43005947)
127. Ehtesham, M., Winston, J. A., Kabos, P. & Thompson, R. C. CXCR4 expression mediates glioma cell invasiveness. Oncogene 25, 2801-2806 (2006).
128. Fernandis, A. Z., Prasad, A., Band, H., Klosel, R. & Ganju, R. K. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 23, 157-167 (2004). (Pubitemid 38142250)
129. Wang, J. et-al. Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cell. Signal. 17, 1578-1592 (2005). (Pubitemid 41253997)
130. Ara, T. Impaired colonization of the gonads by primordial germ cells in mice lacking a chemokine, stromal cell-derived factor-1 (SDF-1). Proc. Natl Acad. Sci. USA 100, 5319-5323 (2003). (Pubitemid 36542703)
131. Plotkin, J., Prockop, S. E., Lepique, A. & Petrie, H. T. Critical role for CXCR4 signaling in progenitor localization and T Cell differentiation in the postnatal thymus. J. Immunol. 171, 4521-4527 (2003). (Pubitemid 37310567)
132. Janas, M. L. et-al. Thymic development beyond β-selection requires phosphatidylinositol 3-kinase activation by CXCR4. J.-Exp. Med. 207, 247-261 (2010).
133. Trampont, P. C. et-al. CXCR4 acts as a costimulator during thymic β-selection. Nature Immunol. 11, 162-170 (2010).
134. Wendt, M. K., Cooper, A. N. & Dwinell, M. B. Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells. Oncogene 27, 1461-1471 (2008). (Pubitemid 351317456)
135. Wendt, M. K. et-al. Silencing of epithelial CXCL12 expression by DNA hypermethylation promotes colonic carcinoma metastasis. Oncogene 25, 4986-4997 (2006).
136. Dimberg, J., Hugander, A., Lofgren, S. & Wagsater, D. Polymorphism and circulating levels of the chemokine CXCL12 in colorectal cancer patients. Int. J. Mol. Med. 19, 11-15 (2007).
137. Hassan, S., Baccarelli, A., Salvucci, O. & Basik, M. Plasma stromal cell-derived factor-1: host derived marker predictive of distant metastasis in breast cancer. Clin. Cancer Res. 14, 446-454 (2008). (Pubitemid 351226112)
138. Drury, L. J., Wendt, M. K. & Dwinell, M. B. CXCL12 chemokine expression and secretion regulates colorectal carcinoma cell anoikis through bim-mediated intrinsic apoptosis. PLoS ONE 5, e12895.
139. Ferguson-Smith, M. The evolution of sex chromosomes and sex determination in vertebrates and the key role of DMRT1. Sex. Dev. 1, 2-11 (2007). (Pubitemid 46709082)
140. Smith, C. A., McClive, P. J., Western, P. S., Reed, K. J. & Sinclair, A. H. Conservation of a sex-determining gene. Nature 402, 601-602 (1999). (Pubitemid 129516320)
141. Veyrunes, F. et-al. Bird-like sex chromosomes of platypus imply recent origin of mammal sex chromosomes. Genome Res. 18, 965-973 (2008). (Pubitemid 351793069)
142. Raymond, C. S. et-al. Evidence for evolutionary conservation of sex-determining genes. Nature 391, 691-695 (1998). (Pubitemid 28113214)
143. Barbaro, M. et-al. Characterization of deletions at 9p affecting the candidate regions for sex reversal and deletion 9p syndrome by MLPA. Eur. J. Hum. Genet. 17, 1439-1447 (2009).
144. Livadas, S. et-al. Gonadoblastoma in a patient with del(9)(p22) and sex reversal: report of a case and review of the literature. Cancer Genet. Cytogenet. 143, 174-177 (2003). (Pubitemid 36629327)
145. Krentz, A. D. et-al. The DM domain protein DMRT1 is a dose-sensitive regulator of fetal germ cell proliferation and pluripotency. Proc. Natl Acad. Sci. USA 106, 22323-22328 (2009).
146. Feldser, D. M., Hackett, J. A. & Greider, C. W. Telomere dysfunction and the initiation of genome instability. Nature Rev. Cancer 3, 623-627 (2003). (Pubitemid 37328834)
147. Hackett, J. A., Feldser, D. M. & Greider, C. W. Telomere dysfunction increases mutation rate and genomic instability. Cell 106, 275-286 (2001). (Pubitemid 32772612)
148. Shen, J. et-al. Short telomere length and breast cancer risk: a study in sister sets. Cancer Res. 67, 5538-5544 (2007). (Pubitemid 46997296)
149. Widmann, T. A., Herrmann, M., Taha, N., Konig, J. & Pfreundschuh, M. Short telomeres in aggressive non-Hodgkin's lymphoma as a risk factor in lymphomagenesis. Exp. Hematol. 35, 939-946 (2007). (Pubitemid 46802988)
150. Wu, X. et-al. Telomere dysfunction: a potential cancer predisposition factor. J. Natl Cancer Inst. 95, 1211-1218 (2003). (Pubitemid 37069551)
151. Fernandez-Garcia, I., Ortiz-de-Solorzano, C. & Montuenga, L. M. Telomeres and telomerase in lung cancer. J. Thorac. Oncol. 3, 1085-1088 (2008).
152. Kang, J. U., Koo, S. H., Kwon, K. C., Park, J. W. & Kim, J. M. Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. Cancer Genet. Cytogenet. 182, 1-11 (2008). (Pubitemid 351323956)
153. Zhang, A. et-al. Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection. Int. J. Cancer 101, 427-433 (2002).
154. Schrader, M. et-al. The differentiation status of primary gonadal germ cell tumors correlates inversely with telomerase activity and the expression level of the gene encoding the catalytic subunit of telomerase. BMC Cancer 2, 32 (2002).
155. Schrader, M. et-al. Quantification of human telomerase reverse transcriptase mRNA in testicular germ cell tumors by quantitative fluorescence real-time RT-PCR. Oncol. Rep. 9, 1097-1105 (2002).
156. Liu, L. et-al. MCAF1/AM is involved in Sp1-mediated maintenance of cancer-associated telomerase activity. J. Biol. Chem. 284, 5165-5174 (2009).
157. Vastermark, K. et-al. Polymorphic variation in the androgen receptor gene: association with risk of testicular germ cell cancer and metastatic disease. Eur. J. Cancer 47, 413-419 (2010).
158. Ferlin, A. et-al. Male infertility and androgen receptor gene mutations: clinical features and identification of seven novel mutations. Clin. Endocrinol. 65, 606-610 (2006). (Pubitemid 44583820)
159. Suzuki, Y. et-al. Screening for mutations of the androgen receptor gene in patients with isolated cryptorchidism. Fertil. Steril. 76, 834-836 (2001). (Pubitemid 32928416)
160. Suzuki, Y. et-al. Mutation screening and CAG repeat length analysis of the androgen receptor gene in Klinefelter's syndrome patients with and without spermatogenesis. Hum. Reprod. 16, 1653-1656 (2001). (Pubitemid 32761745)
161. Wiener, J. S., Marcelli, M., Gonzales, E. T., Jr, Roth,-D. R. & Lamb, D. J. Androgen receptor gene alterations are not associated with isolated cryptorchidism. J. Urol. 160, 863-865 (1998). (Pubitemid 29479545)
162. Aschim, E. L. et-al. Linkage between cryptorchidism, hypospadias, and GGN repeat length in the androgen receptor gene. J. Clin. Endocrinol. Metab. 89, 5105-5109 (2004).
163. Ferlin, A. et-al. Androgen receptor gene CAG and GGC repeat lengths in cryptorchidism. Eur. J. Endocrinol. 152, 419-425 (2005). (Pubitemid 40439495)
164. Radpour, R., Rezaee, M., Tavasoly, A., Solati, S. & Saleki, A. Association of long polyglycine tracts (GGN repeats) in exon 1 of the androgen receptor gene with cryptorchidism and penile hypospadias in Iranian patients. J. Androl. 28, 164-169 (2007). (Pubitemid 46048090)
165. Silva-Ramos, M. et-al. The CAG repeat within the androgen receptor gene and its relationship to cryptorchidism. Int. Braz. J. Urol. 32, 330-335 (2006).
166. Chamberlain, N. L., Driver, E. D. & Miesfeld, R. L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 22, 3181-3186 (1994). (Pubitemid 24260654)
167. Choong, C. S., Kemppainen, J. A., Zhou, Z. X. & Wilson, E. M. Reduced androgen receptor gene expression with first exon CAG repeat expansion. Mol. Endocrinol. 10, 1527-1535 (1996). (Pubitemid 26408742)
168. Brooks, B. P. & Fischbeck, K. H. Spinal and bulbar muscular atrophy: a trinucleotide-repeat expansion neurodegenerative disease. Trends Neurosci. 18, 459-461 (1995).
169. Kazemi-Esfarjani, P., Trifiro, M. A. & Pinsky, L. Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. Hum. Mol. Genet. 4, 523-527 (1995).
170. Czeizel, A., Erodi, E. & Toth, J. Genetics of undescended testis. J. Urol. 126, 528-529 (1981). (Pubitemid 11020110)
171. Elert, A., Jahn, K., Heidenreich, A. & Hofmann, R. Population-based investigation of familial undescended testis and its association with other urogenital anomalies. J. Pediatr. Urol. 1, 403-407 (2005). (Pubitemid 43230264)
172. Toppari, J., Virtanen, H., Skakkebaek, N. E. & Main, K. M. Environmental effects on hormonal regulation of testicular descent. J.-Steroid Biochem. Mol. Biol. 102, 184-186 (2006). (Pubitemid 44750642)
173. Rajpert-De Meyts, E. et-al. The immunohistochemical expression pattern of Chk2, p53, p19INK4d, MAGE-A4 and other selected antigens provides new evidence for the premeiotic origin of spermatocytic seminoma. Histopathology 42, 217-226 (2003). (Pubitemid 36356853)
174. Goriely, A. et-al. Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. Nature Genet. 41, 1247-1252 (2009).
175. McIntyre, A. et-al. Genomic copy number and expression patterns in testicular germ cell tumours. Br. J. Cancer 97, 1707-1712 (2007). (Pubitemid 350249354)
176. Sievers, S. et-al. IGF2/H19 imprinting analysis of human germ cell tumors (GCTs) using the methylation-sensitive single-nucleotide primer extension method reflects the origin of GCTs in different stages of primordial germ cell development. Genes Chromosom. Cancer 44, 256-264 (2005). (Pubitemid 41397094)
177. Verdorfer, I., Rogatsch, H., Tzankov, A., Steiner, H. & Mikuz, G. Molecular cytogenetic analysis of human spermatocytic seminomas. J. Pathol. 204, 277-281 (2004). (Pubitemid 39430086)
178. Looijenga, L. H. et-al. Genomic and expression profiling of human spermatocytic seminomas: primary spermatocyte as tumorigenic precursor and DMRT1 as candidate chromosome 9 gene. Cancer Res. 66, 290-302 (2006).
179. Stoop, H. et-al. Stem cell factor as a novel diagnostic marker for early malignant germ cells. J. Pathol. 216, 43-54 (2008).
180. Read, G. et-al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J. Clin. Oncol. 10, 1762-1768 (1992). (Pubitemid 23059954)
181. Cullen, M. H. et-al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J. Clin. Oncol. 14, 1106-1113 (1996).
182. Gilbert, D. C. et-al. Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapy. BJU Int. 98, 67-69 (2006).
183. Westermann, D. H. et-al. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis. J. Urol. 179, 163-166 (2008).
184. Einhorn, L. H. Treatment of testicular cancer: a new and improved model. J. Clin. Oncol. 8, 1777-1781 (1990).
185. Koberle, B., Masters, J. R., Hartley, J. A. & Wood, R. D. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr. Biol. 9, 273-276 (1999). (Pubitemid 29139312)
186. Masters, J. R. & Koberle, B. Curing metastatic cancer: lessons from testicular germ Cell tumours. Nature Rev. Cancer 3, 517-525 (2003). (Pubitemid 37328839)
187. Feldman, D. R. et-al. Phase-II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Invest. New Drugs 28, 523-528 (2010).
188. Noel, E. E. et-al. The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am. J. Pathol. 176, 2607-2615 (2010).
189. Korkola, J. E. et-al. Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. J. Clin. Oncol. 27, 5240-5247 (2009).
190. Mueller, T. et-al. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance. Tumour Biol. 27, 71-83 (2006).
191. Beyrouthy, M. J. et-al. High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors. Cancer Res. 69, 9360-9366 (2009).
192. Koster, R. et-al. Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J. Clin. Invest. 120, 3594-3605 (2010).
193. Spierings, D. C. et-al. Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis. Oncogene 23, 4862-4872 (2004). (Pubitemid 38937046)
194. Potter, J. D. Morphogens, morphostats, microarchitecture and malignancy. Nature Rev. Cancer 7, 464-474 (2007).
195. Stevens, L. C. The development of transplantable teratocarcinomas from intratesticular grafts of pre- and postimplantation mouse embryos. Dev. Biol. 21, 364-382 (1970).
196. Pierce, G. B. Jr, Dixon, F. J. Jr & Verney, E. L. Teratocarcinogenic and tissue-forming potentials of the cell types comprising neoplastic embryoid bodies. Lab. Invest. 9, 583-602 (1960).
197. Pettersson, A., Richiardi, L., Nordenskjold, A., Kaijser, M. & Akre, O. Age at surgery for undescended testis and risk of testicular cancer. N.-Engl. J.-Med. 356, 1835-1841 (2007). (Pubitemid 46698464)